Satellos releases new Duchenne trial data

Executive Summary

• Satellos Bioscience presented Phase 1a/b data showing SAT‑3247 was safe, well‑tolerated and produced large improvements in grip strength and predicted forced vital capacity in five adult DMD patients.
• The company announced an 11‑month open‑label follow‑up study (adding males aged 16‑25) and a planned global Phase 2 proof‑of‑concept trial in ambulatory children with DMD, with regulatory filings already submitted.

Key Details

• Study Population: 5 adult patients (age 20‑27) with Duchenne muscular dystrophy; 28‑day dosing period.
• Safety: No drug‑related adverse events ≥ moderate severity; no dose‑limiting toxicities observed.
• Pharmacokinetics: Described as “desirable” with exposure correlating to efficacy signals.
• Efficacy – Grip Strength:
• Dominant hand: +118.6 % mean increase in maximum grip strength (≈2 kg → ≈4 kg).
• Non‑dominant hand: +97.9 % mean increase.
• Efficacy – Pulmonary Function: Predicted forced vital capacity improved by +5.8 %, contrary to the typical ~5 % annual decline in this age group.
• Other Measures: All remaining exploratory endpoints remained stable over 28 days.
• Open‑Label Follow‑Up Study (11 months):
• Expands enrollment to additional males with DMD, ages 16‑25.
• Primary endpoints: long‑term safety/tolerability and effect on biceps brachii fat fraction.
• Secondary endpoints: impact on muscle force, function, and fat fraction.
• Interim results expected after the three‑month follow‑up visit.
• Planned Phase 2 Study:
• Design: randomized, double‑blind, placebo‑controlled, global proof‑of‑concept.
• Population: ambulatory children with DMD (age range not specified).
• Primary endpoints: safety/tolerability and muscle force.
• Secondary endpoints: muscle quality, function, regeneration.
• Regulatory filings submitted in the U.S. and internationally.

Notable Quotes

• “Satellos's new and updated clinical results from the 28‑day clinical study in adults with Duchenne provide an important validation of SAT‑3247's potential to be a safe and clinically meaningful treatment,” – Frank Gleeson, Co‑founder & CEO.
• “These early signs of efficacy in adults with more advanced disease are incredibly encouraging and support expanding our clinical program to the broader Duchenne community,” – Wildon Farwell, MD, Chief Medical Officer.